| Title | Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
| Protocole ID | GS-US-352-4365 |
| ClinicalTrials.gov ID | NCT03441113 |
| Cancer Type(s) | Myelodysplastic Syndrome |
| Phase | Phase II |
| Stage | Myelofibrosis |
| Study Type | Treatment |
| Drug | Momelotinib |
| Institution |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
1001 boul. Décarie , Montréal, QC, H4A 3J1 |
| City | |
| Principal Investigator |
Dr. Jonathan How |
| Coordinator |
Judit Kokai 438-888-1582 |
| Status | Recruiting |
| Activation Date | |
| Eligibility Criteria |
|
| Exclusion Criteria |
|
Groupe d'étude en oncologie du Québec